study to evaluate the efficacy of BiPAP/CPAP for the prevention of acute mountain sickness

A Pilot study to evaluate the efficacy of prophylactic BiPAP/CPAP ventilation for the prevention of acute mountain sickness in non-acclimatized individuals - PEPA

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/083607

Enrollment

Registered

2025-03-27

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: T702- Other and unspecified effects of high altitude

Interventions

Intervention1: tab Dimox 5mg OD: tab Dimox 5mg OD for 3 days Orally given to individuals as preventive major Control Intervention1: oxygen gas @5lit/min: oxygen given by hudson mask,@5liter/min on ha

Eligibility

Inclusion criteria

Inclusion criteria: adult male and female of age not more than 60 years, who visited high altitude zone

Exclusion criteria

Exclusion criteria: any coronary artery disease any respiratory disease hypertensive diabetic tubercular treatment bleeding disorder

Design outcomes

Primary

Measure	Time frame
this is pilot trial to evaluate the efficacy of non invasive ventilation for the prevention of the acute mountain sickness in those people who are not acclimatizedTimepoint: 6, 12 and 24 hours	—

Secondary

Measure	Time frame
effect of the dimox tabletTimepoint: 6,12 and 24 hrs	—

Countries

India

Contacts

Public ContactDr Anil Kumar

Maharani Laxmi Bai Medical College Jhansi

dranshulrachna@gmail.com9411685406

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026